New england journal of medicine publishes positive phase 3 trial results for regen-cov™ (casirivimab and imdevimab) to treat covid-19

Tarrytown, n.y., sept. 29, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the new england journal of medicine (nejm) published positive detailed results from a phase 3 trial that assessed the ability of regen-cov™ (casirivimab and imdevimab) to treat covid-19 in infected high-risk non-hospitalized patients (outpatients).
REGN Ratings Summary
REGN Quant Ranking